Wolverine stack research: studies, doses and safety
An unapproved recovery blend with no controlled human trial of the premixed product.
Also called: Wolverine blend, BPC/TB blend.
Community blends · Unapproved BPC-157 and TB-500 mixture; ratios and ingredient identities vary.
Related uncontrolled combination exposures are not studies of a marketed fixed blend. Composition and amounts cannot be assumed equivalent. No verified fixed-blend study count is assigned.
Key studies
- Knee pain: four combination recipients: Pain improved in 3/4 combination and 11/12 BPC-only recipients; this cannot establish benefit of a premixed blend. (source)
- Dental nerve injury: three mixed-treatment cases: All three reported sensory improvement, but other drugs and spontaneous recovery prevent attribution to the peptides. (source)
- Rat tendon repair: no added combination benefit: The pair did not outperform either ingredient alone in this small rat experiment. (source)
- BPC-157: blood-vessel signals: BPC-157 increased vessel growth and VEGFR2–Akt–eNOS signaling in animal and cell experiments. (source)
- Full-length TB4: rat skin wounds: Full-length TB4 increased wound covering in rats; this does not establish effects of the TB-500 fragment. (source)
Related to Wolverine stack (BPC-157 + TB-500)
- KLOW blend: GLOW plus KPV: a four-ingredient community blend with no human study of the combination found.
- GLOW blend (GHK-Cu + BPC-157 + TB-500): An unapproved skin-and-recovery blend with no human combination study found.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Cellulitis, NHS · NHS · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Federal Register: nonbinding draft HHS interim policy, October 30 2026, 2026
- HHS 503A peptide interim enforcement policy and conditions, October 30 2026, 2026
- July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) Meeting, FDA · 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), FDA · 2026
- July 23-24, 2026, Meeting of the Pharmacy Compounding Advisory Committee – FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), FDA · FDA · 2026
- July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026, FDA · FDA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.